NCT02092220已完成不适用
A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 8
- 主要终点
- Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 11
研究概览
简要总结
This study will test the hypothesis that a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults with type 1 diabetes.
Please note that all participants must work or attend school at one of the following campuses: Massachusetts General Hospital in Boston, MA; University of Massachusetts Medical Center in Worcester, MA; University of North Carolina in Chapel Hill, NC; Stanford University in Palo Alto, CA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years and have had clinical type 1 diabetes for at least one year
- •Diabetes managed using an insulin pump for ≥ 6 months
- •Prescription medication regimen stable for > 1 month (except for medications that will not affect the safety of the study and are not expected to affect any outcome of the study, in the judgement of the site principal investigator).
- •Employee or student working or studying during most of the week at one of the participating campuses (Massachusetts General Hospital in Boston, MA; University of Massachusetts Medical Center in Worcester, MA; University of North Carolina in Chapel Hill, NC; Stanford University in Palo Alto, CA)
- •Lives within a 30 minute drive-time radius of the central monitoring location for one of the study sites
- •Willing to remain within a 60 minute drive-time radius of the central monitoring location for one of the study sites during each of the 11-day study arms
- •Have someone over 18 years of age who lives with them, has access to where they sleep, is willing to be in the house when the subject is sleeping, and is willing to receive calls from the study staff and check the welfare of the study subject if telemetry shows a technical problem or severe biochemical hypoglycemia without subject response and the subject does not answer their telephone (up to two individuals can share this role, but they must be willing to carefully coordinate with each other and the subject so that one of them is clearly designated as having this responsibility at any given time)
- •Willing to wear two infusion sets and continuous glucose monitor (CGM) sensor and change sets frequently (at least one new glucagon infusion set daily)
排除标准
- •Unable to provide informed consent (e.g. impaired cognition or judgment)
- •Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision or dexterity that prevents safe operation of the bionic pancreas, impaired memory, unable to speak and read English)
- •Current participation in another diabetes-related clinical trial that, in the judgment of the principal investigator, will compromise the results of this study or the safety of the subject
- •Pregnancy [positive urine human chorionic gonadotropin (HCG)] breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception
- •Need to go outside of the designated geographic boundaries during either arm of the study
- •Current alcohol abuse (intake averaging > 3 drinks daily in last 30 days), use of marijuana within 1 month of enrollment, or other substance abuse (use within the last 6 months of controlled substances other than marijuana without a prescription)
- •Unwilling or unable to refrain from drinking more than 2 drinks in an hour or more than 4 drinks in a day or use of marijuana during the trial
- •Unwilling or unable or to avoid use of drugs that may dull the sensorium, reduce sensitivity to symptoms of hypoglycemia, or hinder decision making during the period of participation in the study (use of beta blockers will be allowed as long as the dose is stable and the subject does not meet the criteria for hypoglycemia unawareness while taking that stable dose, but use of benzodiazepines or narcotics, even if by prescription, may be excluded according to the judgment of the principal investigator)
- •History of liver disease that is expected to interfere with the anti-hypoglycemia action of glucagon (e.g. liver failure or cirrhosis). Other liver disease (i.e. active hepatitis, steatosis, active biliary disease, any tumor of the liver, hemochromatosis, glycogen storage disease) may exclude the subject if it causes significant compromise to liver function or may do so in an unpredictable fashion.
- •Renal failure on dialysis
- •Personal history of cystic fibrosis, pancreatitis, pancreatic tumor, or any other pancreatic disease besides type 1 diabetes
- •Any known history of coronary artery disease including, but not limited to, history of myocardial infarction, stress test showing ischemia, history of angina, or history of intervention such as coronary artery bypass grafting, percutaneous coronary intervention, or enzymatic lysis of a presumed coronary occlusion)
- •Abnormal electrocardiogram (EKG) consistent with coronary artery disease or increased risk of malignant arrhythmia including, but not limited to, evidence of active ischemia, prior myocardial infarction, proximal left anterior descending coronary artery (LAD) critical stenosis (Wellen's sign), prolonged QT interval (> 440 ms). Non-specific ST segment and T wave changes are not grounds for exclusion in the absence of symptoms or history of heart disease. A reassuring evaluation by a cardiologist after an abnormal EKG finding may allow participation.
- •Congestive heart failure (CHF) [established history of CHF, lower extremity edema, paroxysmal nocturnal dyspnea, or orthopnea]
- •History of transient ischaemic attack (TIA) or stroke
- •Seizure disorder, history of any non-hypoglycemic seizure within the last two years, or ongoing treatment with anticonvulsants
- •History of hypoglycemic seizures or coma in the last year
- •History of pheochromocytoma: fractionated metanephrines will be tested in patients with history increasing the risk for a catecholamine secreting tumor:
- •episodic or treatment refractory (requiring 4 or more medications to achieve normotension) hypertension
- •paroxysms of tachycardia, pallor, or headache
- •personal or family history of multiple endocrine neoplasia type 2A (MEN 2A), multiple endocrine neoplasia type 2B (MEN 2B), neurofibromatosis, or von Hippel-Lindau disease
- •History of adrenal disease or tumor
- •Hypertension with systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 despite treatment
- •Untreated or inadequately treated mental illness (indicators would include symptoms such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the last year), or treatment with anti-psychotic medications that are known to affect glucose regulation.
- •Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to radio-frequency (RF) interference
- •Unable to completely avoid acetaminophen for duration of study
- •History of adverse reaction to glucagon (including allergy) besides nausea and vomiting
- •Established history of allergy or severe reaction to adhesive or tape that must be used in the study
- •History of eating disorder such as anorexia, bulimia, or diabulemia or omission of insulin to manipulate weight
- •History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment
- •Use oral [e.g. thiazolidinediones, biguanides, sulfonylureas, glitinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT-2) inhibitors] anti-diabetic medications
- •Lives in or frequents areas with poor Verizon wireless network coverage (which would prevent remote monitoring)
- •Any factors that, in the opinion of the site principal investigator or overall principal investigator, would interfere with the safe completion of the study
研究组 & 干预措施
Bionic Pancreas
Experimental
Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
干预措施: Bionic Pancreas (Device)
Usual Care
Active Comparator
Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
干预措施: Insulin pump with or without CGM (Device)
结局指标
主要结局
Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 11
时间窗: Days 2 to 11 of each period
Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than 60 mg/dL \[3.3 millimoles/liter (mmol/L)\] during Days 2 to 11 was calculated.
Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 11
时间窗: Days 2 to 11 of each period
Glucose reading were taken every 5 minutes by the CGM. The glucose results on Days 2 to 11 were averaged.
次要结局
- Glycated Albumin on Day 12(Day 12 of each period)
- 1,5-anhydroglucitol on Day 12(Day 12 of each period)
- Number of Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)(Days 1-11)
- Percentage of Days That CGM Was Used by Participants as Part of Their Usual Care(Days 1-11 of each period)
- Total Grams of Carbohydrate Taken for Hypoglycemia(Day 1, Days 1 to 11 and Days 2 to 11 of each period)
- Number of Participants With Skin Rash(11 days of each period)
- Percentage of Time With CGMG Concentration by Ranges During Day 1(Day 1 of each period)
- Number of Participants With Severe Hypoglycemic Events(11 days of each period)
- Number of Episodes of Symptomatic Hypoglycemia(Day 1, Days 1 to 11 and Days 2 to 11 of each period)
- Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm(Day 1, Days 2 to 11, Days 1 to 11 of each period)
- Percentage of Time Bionic Pancreas Off-line or Not Functioning Properly(11 days)
- Change From Baseline in Body Weight(Baseline and Day 12 of each period)
- Change From Baseline in Hemoglobin(Baseline and Day 12 of each period)
- Mean CGMG Values(Day 1 and Days 1 to 11 in each period)
- Percentage of Time With CGMG Concentration by Ranges During Days 2 to 11(Days 2 to 11 of each period)
- Anti-Insulin and Anti-Glucagon Antibodies on Day 12(Day 12 of each period)
- Number of Reported Carbohydrate Interventions for Hypoglycemia(Day 1, Days 1 to 11 and Days 2 to 11 of each period)
- Percentage of Time With CGMG Concentration by Ranges During Days 1 to 11(Days 1 to 11 of each period)
- Percentage of Participants With Mean CGMG < 154 mg/dl(Day 1, Days 2 to11, Days 1 to11 of each period)
- Insulin Total Daily Dose(Day 1, Days 1 to 11, Days 2 to 11 of each period)
- Mean Glucose Target Set by User (Time-weighted Average Over Study Period) in the Bionic Pancreas Arm(Day 1, Days 2 to 11, Days 1 to11, Overall, Daytime, Nighttime of each period)
- Mean Nausea Index Score Using a Visual Analog Scale (VAS)(Day 1, Days 1 to 11, Days 2 to 11 and each individual day 2 to 11 of each period)
研究者
Steven J. Russell, MD, PhD
Assistant Professor of Medicine
Massachusetts General Hospital
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine PancreasType 1 DiabetesNCT01762059Massachusetts General Hospital32
已完成
不适用
The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine PancreasType 1 DiabetesNCT02105324Massachusetts General Hospital19
已完成
不适用
Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related DiabetesCystic Fibrosis-related DiabetesNCT03258853Massachusetts General Hospital22
已完成
不适用
The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine PancreasType 1 DiabetesNCT01833988Massachusetts General Hospital32
已完成
不适用
Closed-Loop Glucagon Administration For Hypoglycemia TreatmentType 1 DiabetesNCT02181127Massachusetts General Hospital31